



**iCo Therapeutics Inc (TSX-V: 'ICO')**

760-777 Hornby St. Tel: 604-602-9414  
Vancouver, BC Fax: 604-602-9699  
V6Z 1S4 Canada [www.icotherapeutics.com](http://www.icotherapeutics.com)

**iCo-007: Second Generation Antisense for the Treatment of Diabetic Macular Edema**

Worldwide exclusive rights licensed from ISIS Pharmaceuticals (Nasdaq: ISIS)

- ISIS is iCo's largest shareholder (approx. 14%)
- iCo holds rights to all therapeutic indications with a non-compete on target
- Back-ended milestones

**Diabetic Macular Edema (DME) Market**

- DME is diabetes-related blindness – 22% of all diabetics will experience some form of visual impairment.
- There are no approved therapeutics for Diabetic Macular Edema (DME)
- > 1.6M patients in the US alone
- Diabetes is an explosive problem in the US
- Multi-billion\$ market opportunity
- Limited competitive landscape
- Recent deal for a DME product that had just completed Phase I:
  - **\$50M** upfront for Asian rights. (Santen-MacuSight)

**Differentiated product profile**

- DME appropriate treatment – long duration in eye means less frequent injection
- Injection is the current standard of care in retinal disease management
- Multi-factor approach “VEGF+”
  - Existing competition target VEGF alone
- 2nd generation antisense
  - Potent, specific, and stable
  - iCo's partner, ISIS, holds the predominant patent estate in antisense

## **Clinical Trial**

- Single intravitreal injection in Diffuse Diabetic Macular Edema patients
- 4 cohorts (3, 10, 20 and 30 µM), number of patients =15 patients if no SAE's
- Open-label, dose escalation study

### **Primary outcomes**

- Safety and tolerability of a single intravitreal injection of iCo-007

### **Secondary outcomes**

- Visual acuity
- Retinal thickness (OCT)
- Assessment of systemic PK profile

### **Early results:**

- iCo-007 is durable in the eye, (due to long half-life), a key product differentiator.
- The trial is mid-way and to date, there have been no adverse events of concern.
- While low patient numbers mean the results are not statistically significant, early results show a decrease in retinal thickness, an important indicator in DME.

## **Scientific Background**

- DME is characterized by new blood vessel growth and increased vascular permeability.
- Drug products that prevent the growth of new blood vessels and inhibit increased vascular permeability may have the potential to treat neovascular diseases, including DME.
- Multiple growth factors are implicated in the etiology of diabetic macular edema and diabetic retinopathy in addition to VEGF.
- iCo-007 inhibits c-Raf expression & blocks MAP kinase signaling
- iCo-007 may also be a potential treatment in ovarian cancer as c-Raf is prominent molecular target regulating cellular growth in ovarian cancer.

## **Key Opinion Leaders & Investigators**

iCo is associated with a world-class group of retinal specialists and investigators:

Alan C. Bird, M.D. **Moorfields Eye Hospital**

David S. Boyer, M.D. **Retina-Vitreous Associates Medical Group**

Philip Rosenfeld, M.D., PhD. **Bascom Palmer Eye Institute**

Jason Slakter, M.D. **Vitreous-Retina-Macula Consultants of NY**

Karl Csaky, M.D., PhD. **Duke University**

Scott Cousins, M.D. **Duke University**

Victor Gonzales, M.D., **Valley Retina Institute**